Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort

INTRODUCTION: Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). We undertook a retrospective analysis of consecutive patients diagnosed with sALCL, treated in routine practice, to serve as a benchmark analysis for co...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez-Calle, Nicolas, Kirkwood, Amy A., Lamb, Maxine, Smith, Alex, Khwaja, Jahanzaib, Manos, Kate, Shrubsole, Caroline, Gray, Nicola, Lewis, Katharine, Tivey, Ann, Bishton, Mark J., Hawkes, Eliza, Ahearne, Matthew J., Osborne, Wendy, Collins, Graham P., Illidge, Timothy, Linton, Kim M., Cwynarski, Kate, Burton, Cathy, Fox, Christopher P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280044/
https://www.ncbi.nlm.nih.gov/pubmed/34037958
http://dx.doi.org/10.1007/s12325-021-01764-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280044/
https://www.ncbi.nlm.nih.gov/pubmed/34037958
http://dx.doi.org/10.1007/s12325-021-01764-0

Ejemplares similares